Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Novel approaches in the treatment of myositis and myopathies
Jemima Albayda
,
Lisa Christopher Stine
School of Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
11
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Novel approaches in the treatment of myositis and myopathies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Myopathy
100%
Myositis
100%
Standardized Treatment
50%
Gene Therapy
50%
New Agents
50%
Rituximab
50%
Corticosteroids
50%
Clinical Outcomes
50%
Disease Pathogenesis
50%
Treatment Response
50%
Stem Cell Transplantation
50%
Heterogeneous Groups
50%
Idiopathic Inflammatory Myopathies
50%
Successful Treatment
50%
Refractory Disease
50%
Novel Therapeutic Targets
50%
Response Criteria
50%
Muscle Weakness
50%
Tumour Necrosis Factor Inhibitor (TNFi)
50%
Intravenous Immunoglobulin (IVIg)
50%
Vascular Occlusion
50%
Biological Agents
50%
Therapeutic Guidelines
50%
Traditional Treatment
50%
Resistance Training
50%
Muscle Inflammation
50%
Varying Response
50%
Medicine and Dentistry
Disease
100%
Myopathy
100%
Myositis
100%
Clinical Trial
33%
Biological Product
33%
Treatment Response
33%
Gene Therapy
33%
Clinical Study
33%
Stem Cell Therapy
33%
Rituximab
33%
Immunosuppressant
33%
Immunoglobulin
33%
TNF Inhibitor
33%
Vascular Occlusion
33%
Muscle Weakness
33%
Resistance Training
33%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Myositis
100%
Myopathy
100%
Clinical Trial
33%
Biological Product
33%
Clinical Study
33%
Immunosuppressive Agent
33%
Rituximab
33%
Immunoglobulin
33%
Muscle Weakness
33%
Tumor Necrosis Factor Inhibitor
33%
Blood Vessel Occlusion
33%
Neuroscience
Muscle Disorder
100%
Myositis
100%
Rituximab
50%
Stem Cell
50%
Intravenous Immunoglobulin
50%
TNF Inhibitor
50%